December 9, 2002
PALADIN RETURNS MARKETING RIGHTS FOR DEPOCYTT TO SKYEPHARMA
(Also in PDF format)

October 31, 2002
PALADIN ANNOUNCES RECORD THIRD QUARTER RESULTS
(Also in PDF format)

October 29, 2002
PALADIN LAUNCHES ANDRODERM^® 5MG TESTOSTERONE PATCH
(Also in PDF format)

October 28, 2002
NOTICE OF PALADIN LABS INC. CONFERENCE CALL
(Also in PDF format)

October 16, 2002
PALADIN APPOINTS VICE-PRESIDENT, SCIENTIFIC AFFAIRS
(Also in PDF format)

October 8, 2002
HEALTH CANADA APPROVES REMODULINT
(Also in PDF format)

October 3, 2002
PALADIN LABS AND HYDRO MED SCIENCES SIGN LICENSE AGREEMENT FOR A ONCE YEARLY IMPLANT FOR PROSTATE CANCER
(Also in PDF format)

September 26, 2002
PALADIN NAMED ONE OF CANADA'S FASTEST GROWING TECHNOLOGY COMPANIES
(Also in PDF format)

September 23, 2002
PALADIN AND NOVO NORDISK SIGN DISTRIBUTION AGREEMENT FOR GLUCAGEN^®
(Also in PDF format)

September 5, 2002
PALADIN FILES NEW DRUG SUBMISSION WITH HEALTH CANADA FOR APPROVAL OF STATEX^® SR
(Also in PDF format)

July 31, 2002
PALADIN ANNOUNCES STRONG SECOND QUARTER RESULTS
(Also in PDF format)

July 25, 2002
NOTICE OF PALADIN LABS INC. CONFERENCE CALL
(Also in PDF format)

July 9, 2002
PALADIN RECEIVES REQUEST FROM HEALTH CANADA FOR ADDITIONAL INFORMATION FOR PLAN BT NON-PRESCRIPTION SWITCH SUBMISSION
(Also in PDF format)

June 20, 2002
PALADIN RECEIVES TPD APPROVAL FOR NEW TESTOSTERONE PATCH IN CANADA
(Also in PDF format)

May 24, 2002
PALADIN FILES NEW DRUG SUBMISSION WITH HEALTH CANADA FOR APPROVAL OF CIRCADIN^®
(Also in PDF format)

May 9, 2002
PALADIN ANNOUNCES RECORD FIRST QUARTER REVENUES
(Also in PDF format)

May 7, 2002
NOTICE OF PALADIN LABS INC. CONFERENCE CALL
(Also in PDF format)

May 3, 2002
PALADIN ANNOUNCES FILING OF FINAL PROSPECTUS
(Also in PDF format)

April 15, 2002
PALADIN ANNOUNCES FILING OF PRELIMINARY PROSPECTUS
(Also in PDF format)

March 21, 2002
PALADIN ANNOUNCES THE CLOSING OF A $21 MILLION SPECIAL WARRANT PRIVATE PLACEMENT
(Also in PDF format)

March 12, 2002
PALADIN ANNOUNCES PRIVATE PLACEMENT OF SPECIAL WARRANTS $20 MILLION
(Also in PDF format)

March 8, 2002
PALADIN ANNOUNCES SUBMISSION TO HEALTH CANADA FOR NON-PRESCRIPTION STATUS FOR PLAN B^TM
(Also in PDF format)

February 19, 2002
PALADIN ANNOUNCES THAT HEALTH CANADA ACCEPTS REMODULINT NEW DRUG SUBMISSION FOR PRIORITY REVIEW
(Also in PDF format)

February 14, 2002
PALADIN ANNOUNCES RECORD FINANCIAL RESULTS FOR 2001
(Also in PDF format)

February 12, 2002
PALADIN LABS INC. ANNOUNCES FOURTH QUARTER AND YEAR-END RESULTS CONFERENCE CALL
(Also in PDF format)

January 17, 2002
PHARMACIA AND PALADIN ENTER INTO DISTRIBUTION AGREEMENT FOR CERTAIN ENDOCRINOLOGY AND WOMEN'S HEALTH BRANDS
(Also in PDF format)